1. Report Industry Investment Rating - No information provided in the content. 2. Core Viewpoints of the Report - In 2025Q2, the A-share market showed a volatile upward trend with significant structural differentiation and style rotation. The median return of active equity funds was 1.90%, outperforming major indices such as the CSI 300 and CSI 500. Nearly 70% of stocks in the whole market recorded positive returns [3]. - As of the end of Q2 2025, the total scale of active equity funds was 3.29 trillion yuan, a decrease of 0.04 trillion yuan from the previous quarter. In Q1 2025, there was a net outflow of 113.407 billion yuan from active equity funds [6]. - Different - style and theme fund managers had diverse investment strategies and outlooks. For example, value - style fund managers focused on undervalued traditional assets and looked for opportunities in some consumer and cyclical sectors; growth - style fund managers concentrated on long - term growth companies and adopted a "boom - mining + balanced allocation" strategy [21][23]. 3. Summary According to the Table of Contents 3.1 Active Equity - Type Fund 2025 Second - Quarter Report Data Review 3.1.1 Performance Review - In Q2 2025, the A - share market was volatile. After a brief decline in early April due to US tariff policies, it stabilized from mid - April to mid - May and saw theme rotations since June. The Guozheng 2000 and ChiNext 50 recorded relatively high positive returns of 4.41% and 3.19% respectively. The median return of active equity funds was 1.90%, and the median stock price change was 5.39% [3]. 3.1.2 Scale and Fund Flow - As of the end of Q2 2025, the total scale of active equity funds was 3.29 trillion yuan, down from 3.33 trillion yuan in the previous quarter. In Q1 2025, there was a net outflow of 113.407 billion yuan from active equity funds. Funds with a fund - flow change ratio < - 1% accounted for 74.34%, while those with a net inflow ≥ 1% accounted for only 16.51% [6]. 3.1.3 Position Change - As of Q2 2025, the average stock position of active equity funds was 87.23%, with an average position change of 1.15%. The average active position change was 1.18%, and the average natural position change was - 0.04%. 39.57% of funds adjusted their active positions by 0 - 5%, and 33.76% adjusted by - 5% - 0 [9]. 3.1.4 Industry Allocation - The top five industries for increased holdings were communication, medicine, non - bank finance, banking, and national defense and military industry. The top five industries for reduced holdings were food and beverage, automobile, commerce and retail, power equipment and new energy, and machinery. Five industries had over - allocation reductions, and nine industries had under - allocation increases [12]. 3.1.5 Individual Stock Heavy - Holdings - The top ten heavy - holding stocks by market value included Tencent Holdings, CATL, Kweichow Moutai, etc. The top ten heavy - holding stocks by the number of holding funds included CATL, Tencent Holdings, Zijin Mining, etc. The stocks with the largest increase in market value of heavy - holdings included Zhongji Innolight, New H3C Semiconductor Technology, etc., while those with the largest decrease included BYD, Alibaba - W, etc. [15][16][18] 3.2 Second - Quarter Report Fund Manager Views Summary 3.2.1 Value Style - Since 2022, value - style funds have attracted more attention. In 2025, they faced headwinds. Many value - style fund managers believed that undervalued stocks were still worth buying. In terms of position structure, most did not significantly adjust their allocations and focused on traditional undervalued assets, while also looking for opportunities in some consumer and cyclical sectors [21]. 3.2.2 Growth Style - Affected by overseas uncertainties and domestic policies, the market was volatile. Growth - style fund managers adhered to selecting long - term growth companies and adopted a "boom - mining + balanced allocation" strategy. They focused on AI, innovation drugs, and some emerging consumption sectors [23]. 3.2.3 Balanced Style - Balanced - style fund managers selected stocks from multiple dimensions and controlled portfolio risks through diversification. In the context of increased market risk appetite, many reduced holdings in traditional industries and high - dividend consumer stocks and increased holdings in growth stocks and booming industries [25]. 3.2.4 Consumption Theme - Traditional consumption showed differentiation and repair. New consumption had structural opportunities, but the sustainability and space of consumption trends needed to be judged. Some fund managers made structural adjustments in traditional consumption and increased investment in new consumption [27]. 3.2.5 Medicine Theme - Innovation drugs became a consensus. Some fund managers also looked for investment targets with low growth this year, such as innovative medical devices, CXO, and pharmacies [29]. 3.2.6 TMT Theme - The AI industry chain developed rapidly. TMT - theme fund managers continued to focus on AI - related companies and also paid attention to other technology sectors such as robotics and semiconductors [31]. 3.2.7 High - End Manufacturing - The attention to the military industry increased. High - end manufacturing showed competitive advantages, and some fund managers expected the recovery of some electro - new energy sectors [33]. 3.2.8 Cycle Theme - Resource sectors had long - term investment logic. Dividend - type cycle assets had allocation significance, and banks were still the core of the dividend sector [35]. 3.2.9 Hong Kong Stock Theme - Most fund managers were relatively optimistic about Hong Kong stocks. Some adjusted their positions from crowded sectors to the technology sector with lower valuations and expected performance growth [37].

7月24日，市场继续大涨，近4400只个股上涨，914只个股下跌，79只个股涨停，1只个股跌停。 高位股，雅下水电概念恒立钻具30CM4连板，深水规院20CM4连板，中国电建、保利联合、西藏天路、高争民爆、西宁特钢、山河智能4连板，中设股份上 演"地天板"录得4连板。海南相关个股凯撒旅业6天3板、康芝药业20CM涨停，千亿权重中国中免涨停。创新药南京新百2连板，年报增长彩虹集团2连板。 | | 代码 | 名称 | 几天几板 价格 | 涨幅% 涨停分析 | 换手率 | 成交额 | 首次涨停时间 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 002542 | 中化岩土 | 6天4板 5.01 | +10.11% 岩土工程+低空经济+国企+中 | 24.22% | 20.51亿 | 09:42:45 | | 2 | 601669 | 中国电建 | 4连板 7.45 | +10.04% 雅 水电概念+水电风电+抽水 | 17.09% | 158.57亿 | 10:45:00 | | 3 | 002037 | 保利联合 | 4连板 14.19 | + ...

见习记者 储是 7月24日，恒生指数上涨0.51%，报收于25667.18点；恒生科技指数下跌0.05%，报收于5743点；恒生国企指数上涨0.18%，报收于9257.62点。市场成交额 为2948.11亿港元，南向资金净买入37.19亿港元。 【导读】今日，港股三大指数涨跌不一，有色金属、非银金融和半导体板块表现较优 | HSI | 恒生指数 | 25667.18c | 129.11 | 0.51% | 2948亿 | | --- | --- | --- | --- | --- | --- | | HSTECH | 恒生科技 | 5743.00c | -2.74 | -0.05% | 765亿 | | HSCEI | 恒生中国企业指数 | 9257.62c | 16.42 | 0.18% | 951亿 | 盘面上，有色金属、非银金融继续上涨，半导体股拉升，大型科网股涨跌不一。 泡泡玛特创始人王宁今日接受央视新闻专访，预告了下一季新款Labubu，泡泡玛特午后拉升。 中金报告显示，年内南向净流入规模已达到7974.5亿港元，接近去年全年水平。中金公司最新分析了港股资金面和未来演变。 非银金融板块上涨 中资券商 ...

Market Overview - The Hang Seng Index rose by 0.51% to close at 25,667.18 points, while the Hang Seng Tech Index fell by 0.05% to 5,743 points, and the Hang Seng China Enterprises Index increased by 0.18% to 9,257.62 points [2][3] - The market turnover was HKD 2,948.11 million, with net inflows from southbound funds amounting to HKD 37.19 million [2][3] Sector Performance - The non-bank financial sector continued to rise, with notable gains in Chinese brokerage stocks such as Guolian Minsheng, Dongfang Securities, and Everbright Securities [7][8] - The insurance sector saw increases, with China Life and Ping An rising by 3.23% and 2.03% respectively [10] - The metals sector experienced significant gains, particularly in lithium stocks, with Tianqi Lithium and Ganfeng Lithium rising over 10% [12] - The semiconductor sector showed active trading, with leading companies Huahong Semiconductor and SMIC increasing by 6.99% and 3.08% respectively [14] Notable Company News - Pop Mart's founder Wang Ning announced new Labubu products in a CCTV interview, leading to a 4.37% increase in the company's stock price [20] - Wang highlighted the overwhelming demand for Labubu, stating that supply chain optimization is ongoing due to the complexity of the product [20] Fund Flow Analysis - According to a report by CICC, the net inflow of southbound funds has reached HKD 797.45 billion this year, nearing last year's total of HKD 807.87 billion [6][21] - Southbound trading now accounts for 35% of total transactions, indicating its growing importance in the market [21] - CICC suggests shifting focus from short-term overstretched banks to insurance stocks and from new consumption to AI applications and innovative pharmaceuticals for growth opportunities [21]

Core Viewpoint - The article emphasizes the importance of long-term value investing in the innovative pharmaceutical sector, highlighting the successful strategies employed by Zheng Ning, a fund manager at Zhongyin Fund, who has achieved significant returns by investing in innovative drugs during market downturns and focusing on long-term pricing rather than short-term fluctuations [1][2][3]. Group 1: Investment Strategy - Zheng Ning's investment approach is characterized by a focus on long-term pricing, filtering out short-term noise and market fluctuations, which distinguishes him from many growth stock fund managers [3][12]. - He has demonstrated a willingness to take contrarian positions, investing heavily in innovative drugs when the market was pessimistic and shifting focus to less popular sectors as the market evolves [3][4][30]. - The performance of his funds, such as Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed A, which achieved an 84.18% return over the past year, reflects the effectiveness of his strategy [2]. Group 2: Market Insights - The innovative pharmaceutical sector is experiencing a collective explosion in growth, with significant revenue increases and profitability improvements among companies in this space [2][23]. - Zheng Ning believes that the current competitive landscape in China's innovative drug market is undergoing rapid changes due to policy shifts, which could lead to substantial opportunities for well-positioned companies [21][22]. - The article notes that the success of Chinese innovative drugs in international markets is a surprising development, with companies generating substantial overseas revenue [24]. Group 3: Risk Management - Zheng Ning emphasizes the importance of being responsible for every position held in the portfolio, focusing on risk-reward ratios rather than short-term performance rankings [4][29]. - He advocates for a balanced approach to investing, suggesting that maintaining a stable life outside of work can enhance investment performance [57]. - The article highlights the need for investors to be cautious at market peaks and to recognize when to take profits, contrasting this with the opportunities available at market bottoms [36][50]. Group 4: Future Outlook - Looking ahead, Zheng Ning is optimistic about the continued growth of the innovative pharmaceutical sector but is also exploring investment opportunities in domestic demand sectors that are currently undervalued [45][46]. - He anticipates that as the market matures, the investment landscape will shift towards higher risk and lower win rates, similar to trends observed in the U.S. market [22][24]. - The article concludes with Zheng Ning's assertion that he is not solely an innovative drug fund manager but rather a broader pharmaceutical industry manager, indicating potential shifts in his investment focus as market conditions change [48][49].

Group 1 - The A-share market indices have reached new closing highs for the year, with the Shanghai Composite Index up 0.65% to 3605.73 points, the Shenzhen Component up 1.21% to 11193.06 points, and the ChiNext Index up 1.5% to 2345.37 points [2] - Nearly 4400 stocks rose in the market, with around 80 stocks hitting the daily limit up, particularly in the Hainan Free Trade Zone concept stocks and financial sectors [2] - Dongguan Securities suggests that the continuous release of capital market reform dividends and policies aimed at attracting medium to long-term funds are expected to create a virtuous cycle of "increased returns - influx of funds - market stability" [2] Group 2 - The market is gradually forming an upward trend, with significant improvement in the profit-making effect, indicating a potential slow bull market [4] - Current market trading volume has started to increase, reaching around 1 trillion to 2 trillion yuan, with volumes below 2 trillion considered normal [4] - The overall market is still characterized by a technology bull market, benefiting from policy support, with technology-related sectors likely to continue leading the market in the second half of the year [4] Group 3 - The pressure line around 3600 to 3700 points is viewed as a psychological barrier rather than a significant trading pressure line, suggesting that breaking through these levels is feasible [5] - Economic data indicates a stable and improving economic performance, with multiple key indicators showing positive trends, which, along with policy support, is expected to boost market expectations [5] - The main upward trends may rotate among sectors such as artificial intelligence, military industry, resource products, and innovative pharmaceuticals [5]

Group 1: Fund Management Updates - Wang Lang has been appointed as the new deputy general manager of Baoying Fund as of July 22, 2023, previously holding positions at Penghua Fund and Guoshou Anbao Fund [1] - As of the end of Q2 2023, there are 24 funds with over 10 billion yuan in assets, a decrease from 27 funds in the same period last year and 26 funds at the end of Q1 2023 [2] - The largest fund remains the E Fund Blue Chip Select managed by Zhang Kun, with a latest size of 34.943 billion yuan, down by 3.965 billion yuan from the end of Q1 [2] Group 2: Market Trends and Performance - The allocation ratio of public funds to Sci-Tech Innovation Board stocks reached a record high of 15.36% by the end of Q2 2023, an increase of 0.19 percentage points from Q1 [3] - The excess allocation ratio for the Sci-Tech Innovation Board also rose from 7.5% to 7.72% [3] Group 3: Notable Fund Manager Insights - Fund manager Ge Lan expressed optimism about the innovative drug sector, highlighting advancements in dual antibodies and ADC technologies, as well as increasing collaboration between domestic companies and multinational pharmaceutical firms [4] - Ge Lan noted that domestic innovative drugs are gaining global recognition, with multiple products expected to have overseas licensing opportunities [4] Group 4: ETF Market Overview - The market experienced a rally with major indices reaching new highs; the Shanghai Composite Index rose by 0.65%, the Shenzhen Component Index by 1.21%, and the ChiNext Index by 1.5% [5] - The total trading volume in the Shanghai and Shenzhen markets was 1.84 trillion yuan, a decrease of 199 billion yuan from the previous trading day [5] - Rare earth permanent magnet stocks surged, with the Rare Metal ETF rising by 7.49% [6] Group 5: Future Outlook - Despite rising geopolitical tensions, improvements in global supply and demand, along with low inventory levels, are expected to boost small metal prices, enhancing corporate profitability and growth potential [9] - The valuation attractiveness of industry leaders is expected to become more pronounced, with a focus on rare metal-related ETFs [9]

Group 1 - The current market environment favors the technology and innovation sectors, with the ChiNext Index representing a low valuation large-cap growth style that is expected to benefit significantly [1] - The ChiNext Index currently has a PE ratio of 33.89 times, which is at the 23.82% percentile over the past decade, indicating it is among the lowest valuation levels in mainstream broad-based indices [1] - New growth drivers such as AI (computing power), innovative pharmaceuticals, and new energy vehicles are experiencing cyclical turning points, providing fundamental support for the low valuation large-cap growth sector [1] Group 2 - The Sci-Tech Innovation and Entrepreneurship ETF (588360) tracks the Sci-Tech Innovation and Entrepreneurship 50 Index (931643), which can have daily fluctuations of up to 20% [1] - The index is compiled by China Securities Index Co., Ltd., selecting high-quality listed companies from the Sci-Tech Innovation Board and ChiNext market in fields such as new-generation information technology, biomedicine, and new materials [1] - The index focuses on technology companies with high growth characteristics, highlighting significant coverage of high-tech industries [1]

Group 1 - The overall market experienced a collective rise, with the pharmaceutical and biotechnology sector showing significant gains, particularly the vaccine ETF (159643) which increased by over 5% [1] - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized drug procurement, which includes 55 drug varieties across various therapeutic areas, such as chemical drugs and biosimilars [3] - The NHSA has established a clear principle of "no procurement for new drugs, procurement for non-new drugs," which delineates the boundary between old drug procurement and new drug protection, providing stable policy expectations for the innovative drug industry [3] Group 2 - It is projected that 2025 will be a pivotal year for the overseas expansion of Chinese innovative drugs, with numerous products expected to exceed peak sales of $3 billion to $5 billion, and record-breaking licensing transactions [4] - Domestic policy adjustments regarding the medical insurance catalog and the promotion of commercial insurance are seen as significant catalysts for investment opportunities in the innovative drug sector [4] - Chinese innovative drugs are recognized for their high efficiency and low-cost development advantages, particularly in competitive areas such as ADC, bispecific antibodies, and cell therapy, suggesting potential investment in innovative drug ETFs like Guotai (517110) [4]

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi showed a turnover rate of 16.97% with a transaction volume of 33.88 million yuan, indicating active market trading [2] - Over the past year, the Kexin Pharmaceutical ETF has seen a significant growth in scale, increasing by 119 million yuan, ranking first among comparable funds [2] - The net asset value of the Kexin Pharmaceutical ETF has risen by 48.37% over the past year, placing it in the top 15.05% among index equity funds [2] Group 2: Stock Performance - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading stocks including United Imaging Healthcare and BeiGene [2] - Recent stock performance includes United Imaging Healthcare with a rise of 2.04% and BeiGene with a slight increase of 0.21%, while Huatai Medical saw a decline of 2.71% [4] Group 3: Industry Trends - The biopharmaceutical industry is entering a dual-driven phase of policy and technology, with innovation drug support policies advancing to phase 2.0 [5] - The medical device sector is experiencing a core trend of replacement and technology export, with regulatory upgrades promoting innovation and industry breakthroughs [5] - State-owned capital entering the biopharmaceutical sector is injecting financial vitality, accelerating R&D investment and industry chain integration [5] Group 4: Licensing Agreements - Chinese innovative pharmaceutical companies are reporting significant "Licence Out" transactions, with Kexin Pharmaceuticals announcing a deal with ERIGEN for an exclusive overseas licensing agreement worth up to 1.32 billion USD [4]